Digital PCR Market Top Segments and Future Trends

Market growth influenced due to following factors-

• Rising incidences of infectious diseases (such as HIV, tuberculosis, and malaria) and genetic disorders.
• Continuous technological advancements in PCR technologies and the commercialization of lab-on-chip devices and microfluidics-based portable instruments.
• Increasing investments, funds, and grants for genomic research.
• Increasing use of biomarker profiling for disease diagnostics.

Global market size-

According to the new market research report dPCR qPCR market is projected to reach $7.6 billion by 2025, at a CAGR of 9.0% .

Leading Players-

The prominent players operating in the dPCR and qPCR market are Thermo Fisher Scientific (US), Bio-Rad Laboratories Inc. (US), and F. Hoffmann-La Roche, Ltd. (Switzerland).

Top Market Segments-

The qPCR reagents & consumables segment is expected to command the largest share of the qPCR products & services market. Factors such as the expanding applications of qPCR (owing to its technological benefits over traditional PCR, such as real-time analysis and reduced analysis time), growing private-public funding for life sciences research, and the rising number of probe-based multiplex genetic analysis procedures (that require the analysis of low-volume gene samples) are expected to drive the growth of the qPCR reagents and consumables market.

The hospitals and diagnostic centres segment is expected to dominate the qPCR market in 2019. The large share of this segment is attributed to the increasing market availability of qPCR reagents in clinical diagnostic applications; ongoing expansion of healthcare infrastructure across emerging countries; high prevalence & incidence of target diseases; and growing awareness on the benefits of qPCR. 

For Details, Download PDF Brochure

Geographic Overview -

North America accounted for the largest share of the digital PCR qPCR market in 2019, followed by Europe. The large share of North American dPCR qPCR market is mainly due to the rising number of genome-based drug development activities undertaken by US-based pharmaceutical and biotechnology companies, increasing support for the development of dPCR and qPCR technologies, a growing target patient base, and the focus on early and effective disease diagnosis.